Literature DB >> 19000913

Zinc regulates the dopamine transporter in a membrane potential and chloride dependent manner.

Christian Pifl1, Alexandra Wolf, Patrick Rebernik, Harald Reither, Michael L Berger.   

Abstract

The dopamine transporter (DAT), a membrane protein specifically expressed by dopaminergic neurons and mediating the action of psychostimulants and dopaminergic neurotoxins, is regulated by Zn(2+) which directly interacts with the protein. Herein, we report a host-cell-specific direction of the Zn(2+) effect on wild type DAT. Whereas low mumolar Zn(2+) decreased dopamine uptake by DAT expressing HEK293 cells, it stimulated uptake by DAT expressing SK-N-MC cells. Inhibition or stimulation was lost in a DAT construct without the binding site for Zn(2+). Also reverse transport was differentially affected by Zn(2+), dependent on whether the DAT was expressed in HEK293 or SK-N-MC cells. Pre-treatment of DAT expressing cells with phorbol-12-myristate-13-acetate, an activator of protein kinase C, attenuated the inhibitory effect of Zn(2+) on uptake in HEK293 cells and increased the stimulatory effect in SK-N-MC cells. Patch-clamp experiments under non-voltage-clamped conditions revealed a significantly higher membrane potential of HEK293 than SK-N-MC cells and a reduced membrane potential after phorbol ester treatment. Lowering chloride in the uptake buffer switched the stimulatory effect of Zn(2+) in SK-N-MC cells to an inhibitory, whereas high potassium depolarization of HEK293 cells switched the inhibitory effect of Zn(2+) to a stimulatory one. This study represents the first evidence that DAT regulation by Zn(2+) is profoundly modulated by the membrane potential and chloride.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19000913     DOI: 10.1016/j.neuropharm.2008.10.009

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  14 in total

1.  Studies of the biogenic amine transporters. 14. Identification of low-efficacy "partial" substrates for the biogenic amine transporters.

Authors:  Richard B Rothman; John S Partilla; Michael H Baumann; Catrissa Lightfoot-Siordia; Bruce E Blough
Journal:  J Pharmacol Exp Ther       Date:  2012-01-23       Impact factor: 4.030

2.  Evidence for noncompetitive modulation of substrate-induced serotonin release.

Authors:  Richard B Rothman; Michael H Baumann; Bruce E Blough; Arthur E Jacobson; Kenner C Rice; John S Partilla
Journal:  Synapse       Date:  2010-11       Impact factor: 2.562

3.  Interaction of catechol and non-catechol substrates with externally or internally facing dopamine transporters.

Authors:  Ying-Jian Liang; Juan Zhen; Nianhang Chen; Maarten E A Reith
Journal:  J Neurochem       Date:  2009-03-11       Impact factor: 5.372

4.  Neural and cardiac toxicities associated with 3,4-methylenedioxymethamphetamine (MDMA).

Authors:  Michael H Baumann; Richard B Rothman
Journal:  Int Rev Neurobiol       Date:  2009       Impact factor: 3.230

Review 5.  The reverse operation of Na(+)/Cl(-)-coupled neurotransmitter transporters--why amphetamines take two to tango.

Authors:  Harald H Sitte; Michael Freissmuth
Journal:  J Neurochem       Date:  2009-11-05       Impact factor: 5.372

Review 6.  Chloride requirement for monoamine transporters.

Authors:  Louis J De Felice
Journal:  Pflugers Arch       Date:  2016-01-22       Impact factor: 3.657

7.  Studies of the biogenic amine transporters. 13. Identification of "agonist" and "antagonist" allosteric modulators of amphetamine-induced dopamine release.

Authors:  Richard B Rothman; Christina M Dersch; Subramaniam Ananthan; John S Partilla
Journal:  J Pharmacol Exp Ther       Date:  2009-02-24       Impact factor: 4.030

8.  Behavioral and dopamine transporter binding properties of the modafinil analog (S, S)-CE-158: reversal of the motivational effects of tetrabenazine and enhancement of progressive ratio responding.

Authors:  Renee A Rotolo; Predrag Kalaba; Vladimir Dragacevic; Rose E Presby; Julia Neri; Emily Robertson; Jen-Hau Yang; Merce Correa; Vasiliy Bakulev; Natalia N Volkova; Christian Pifl; Gert Lubec; John D Salamone
Journal:  Psychopharmacology (Berl)       Date:  2020-08-07       Impact factor: 4.530

9.  Early-life metal exposure and schizophrenia: A proof-of-concept study using novel tooth-matrix biomarkers.

Authors:  A Modabbernia; E Velthorst; C Gennings; L De Haan; C Austin; A Sutterland; J Mollon; S Frangou; R Wright; M Arora; A Reichenberg
Journal:  Eur Psychiatry       Date:  2016-06-14       Impact factor: 5.361

10.  Schizophrenia: redox regulation and volume neurotransmission.

Authors:  I Bókkon; I Antal
Journal:  Curr Neuropharmacol       Date:  2011-06       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.